Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:19Psychoneuroimmunology: Diabetes and Cancer
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Sexual dimorphism in the DNA methylation pattern after immune stimulation in the zebrafish (<i>Danio rerio</i>) gonads.
Frontiers in cell and developmental biology·2026
Same author
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.
Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Related Experiment Video
Updated: Jun 12, 2026
08:19
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
[Etanercept and neoplasms].
A García-Rabasco1, J L Sánchez-Carazo, A Esteve
1Servicio de Dermatología, Consorcio Hospital General Universitario, Valencia, España. anagrabasco@gmail.com
Actas Dermo-Sifiliograficas
|May 25, 2010
Summary
Tumor necrosis factor (TNF) blockers significantly advance inflammatory disease treatment but may increase neoplasm risk. A psoriasis patient developed breast cancer after etanercept, highlighting this debated adverse effect.
Area of Science:
- Immunology
- Oncology
- Dermatology
Background:
- Tumor necrosis factor (TNF) blockers represent a therapeutic advance for inflammatory diseases like psoriasis.
- TNF is crucial for immune surveillance against infections and neoplasms.
Observation:
- A long-standing psoriasis patient developed breast adenocarcinoma following etanercept treatment.
- This case highlights a potential adverse effect of anti-TNF therapy.
Findings:
- The use of anti-TNF agents, including etanercept, is debated regarding an increased risk of neoplasm development.
- Literature suggests associations between anti-TNF therapy and certain cancers, such as leukemias, lymphomas, and solid tumors.
Implications:
